US · Healthcare · Medical Instruments & Supplies
EPS came in at 2.55 against a street estimate of 1.91 — a beat of 33.5%.
Analysts rate Solventum Corp. a hold (3 buy, 8 hold, 1 sell out of 12) with an average price target of $93.92.
CONFIDENT Solventum beat Q2 expectations on organic growth and EPS despite complex ERP cutovers. Announced HIS separation to unlock value and sharpen MedTech focus. Raised 2026 guidance on strong execution and tariff refunds. Q2 FY26 Call did not break out regional performance separately. Analysts pressed on HIS rationale (why separate a high-growth business?), market demand durability, and capital allocation post-transaction. Management emphasized AI-driven autonomous coding upside, resilient market health, and balanced capital discipline without shifting to large M&A. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| Independent Franchise Partners LLP | 9.50% |
| BlackRock Inc | 6.16% |
| Vanguard Capital Management, LLC | 5.64% |
| Trian Fund Management LP | 4.84% |
| State Street Corp | 3.76% |
| Vanguard Portfolio Management, LLC | 3.75% |
| Davis Selected Advisers | 3.71% |
| Geode Capital Management, LLC | 2.79% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 SOLVENTUM CORPORATION - FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Total Net Sales (6 months): $4,216 million (2025: | 2026-08-05 |
| Results announced · Q3 2026 SOLVENTUM Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Sales: $2,209 million, up 2.2% reported; up 9.5% on organic basis • Q2 2026 A | 2026-08-05 |
| Reg FD disclosure · Q3 2026 SOLVENTUM CORPORATION (SOLV) – FORM 8-K SUMMARY HEADLINE NUMBERS • No specific financial figures disclosed in this filing • Document dated August 5, | 2026-08-05 |
| Board / officer change · Q3 2026 SOLVENTUM CORPORATION – FORM 8-K SUMMARY Report Date: July 16, 2026 --- HEADLINE NUMBERS • Neil Zieselman appointed Senior Vice President, Controll | 2026-07-20 |
| Company announcement · Q2 2026 SOLVENTUM CORPORATION (SOLV) — FORM 8-K SUMMARY HEADLINE NUMBERS • Settlement payment: $120,000 in attorneys' fees and expenses • Filing date: June | 2026-06-05 |
| Quarterly report · Q1 2026 SOLVENTUM CORPORATION – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total net sales (Q1 2026): $2,007 million, down from $2,070 million in Q1 2025 (−0.9 | 2026-05-05 |
| Proxy statement · Q4 2025 SOLVENTUM CORPORATION PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of 4 Class II Directors — Carlos Albán, Shirley Edwards, | 2026-03-27 |
| Annual report FY2025 SOLVENTUM CORPORATION – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Fiscal Year Ended: December 31, 2025 • Market Cap: Approximately $13.1 | 2026-02-27 |
Readable in the app.
| Announcement | Date |
|---|---|
| Announced intention to pursue separation of Health Information Systems business Solventum Corporation announced on August 5, 2026, its intention to separate its Health Information Systems business as part of ongoing portfolio optimization. This is a strategic restructur | 2026-08-05 |
| Fourth-quarter 2025 results reported and 2026 full-year guidance introduced Solventum Corporation filed an 8-K form on February 26, 2026, to disclose that it had issued a press release reporting its fourth-quarter 2025 financial results and providing guidance for fu | 2026-02-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Solventum Corp. — free to start.
Google PlayApp StoreData updated 2026-09-18.